Skip to content
Research Article Open access CC BY 4.0

Tumor Therapy with Amanita phalloides: Benefits and Limitation

Isolde Riede

Journal of Complementary and Alternative Medical Research · pp. 29–37 · Published 6 Mar 2021

10.9734/jocamr/2021/v13i130217

Abstract

Background: Classical tumor treatments can fail: surgeries, radiation and chemotherapy not always elongate the life span. Less destructive treatments are possible nowadays. To find and analyse the efficiency of alternate treatments, long term case reports are essential. Aim: To determine long term analyses of Amanita treatment in patients with different tumor types. Methods: Patients are treated with Amanita alone, as long as the tumor growth of cells can be retarded. Other anti tumor therapies are applied in addition, when the retardation of the tumor growth is not sufficiently manageable with Amanita alone. The treatments with Amanita are supported by application of Terebinthina laricina in intervals to eliminate Borrelia. Results: The state of a patient with a thyroid-carcinoma and a rectum-carcinoma can be stabilized for ten years with Amanita alone, until her age of 90 years. The patient cannot further tolerate uptake of Amanita. Thyroid cells start to grow, rectum-carcinoma cells grow slower. The disease state of a patient with prostate-carcinoma can be stabilized with Amanita alone for six years. Other therapies are applied from then on in intervals in addition for further six years. No chemotherapy or radiation is applied. The patient died at the age of 84 with metastases. A patient with B-cell chronic lymphatic leukemia is treated with Amanita as sole antitumor therapy for eleven years. After that period, no further antitumor treatment is necessary, the patient lives now with high but stable leukocyte count for two years after the end of the Amanita therapy. Conclusions: Amanita can inhibit tumor growth of different tumor types for a long period of time, elongation of the life span is possible. A synergistic effect of anti-Borrelia treatment is observed. Occasionally the tumor growth of cells stops without further anti tumor therapy, and no correlation with the origin can be identified.

Amanita phalloides thyroid-Ca rectum-Ca prostata-Ca B-cell chronic lymphatic leukemia.

References (11)

  1. 1 Radiotherapy and Short-Term Androgen Deprivation for Localized Prostate Cancer [DOI]
  2. 2 Papillary Thyroid Cancer: Genetic Alterations and Molecular Biomarker Investigations [DOI]
  3. 3 Stomach cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study [DOI]
  4. 4 Depth and durability of response to ibrutinib in CLL: 5-year follow-up of a phase 2 study [DOI]
  5. 5 Colon cancer survival in the United States by race and stage (2001‐2009): Findings from the CONCORD‐2 study [DOI]
  6. 6 Switch the Tumor Off: From Genes to Amanita Therapy [DOI]
  7. 7 Borrelia Infection Appears as Chronic Lymphocytic Leukemia: Therapy with Amanita phalloides and Terebinthina laricina [DOI]
  8. 8 Stabilization of Prostate Cancer with Amanita phalloides: Intervals with 5-Alpha-Reductase Inhibitors and Melatonin to Circumvent Resistance: Case Report [DOI]
  9. 9 Stabilization of Chronic Lymphatic Leukemia with Amanita phalloides: Effect of Additional Chelidonium majus. Case Report [DOI]
  10. 10 Amanita Phalloides Avoids Tumor Growth of Leukocytes with Philadelphia Chromosome: Case Report [DOI]
  11. 11 Genes in Tumor Formation [DOI]

Cited by 0

No indexed citations yet.

Related research

Article metrics

Real usage data collected on this platform.

41

Page views

0

PDF downloads

3

Outbound clicks

0

Citations

Views over time

Views by country

Approximate, from request IP at view time — not citizenship or institution. Countries with fewer than 5 views are grouped as "Other".

Traffic sources

Referring site, by host.

Views and downloads exclude known bots/crawlers. Citations combines this platform's own DOI-resolved index with each external source's own reported total — see Cited by above for individually listed citing works. Last refreshed 0 seconds ago.